As of 2026-04-04, the Relative Valuation of Regenxbio Inc (RGNX) is (77.39) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.53 USD, the upside of Regenxbio Inc based on Relative Valuation is -1007.2%.
The range of the Relative Valuation is (77.24) - (81.44) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.4x - 23.5x | 20.4x |
| Forward P/E multiples | 20.6x - 21.7x | 20.8x |
| Fair Price | (77.24) - (81.44) | (77.39) |
| Upside | -1005.5% - -1054.8% | -1007.2% |
| Date | P/E |
| 2026-04-01 | -2.30 |
| 2026-03-31 | -2.23 |
| 2026-03-30 | -2.07 |
| 2026-03-27 | -2.07 |
| 2026-03-26 | -2.20 |
| 2026-03-25 | -2.25 |
| 2026-03-24 | -2.08 |
| 2026-03-23 | -2.22 |
| 2026-03-20 | -2.16 |
| 2026-03-19 | -2.23 |
| 2026-03-18 | -2.20 |
| 2026-03-17 | -2.30 |
| 2026-03-16 | -2.34 |
| 2026-03-13 | -2.28 |
| 2026-03-12 | -2.42 |
| 2026-03-11 | -2.50 |
| 2026-03-10 | -2.64 |
| 2026-03-09 | -2.76 |
| 2026-03-06 | -2.30 |
| 2026-03-05 | -2.32 |
| 2026-03-04 | -2.43 |
| 2026-03-03 | -2.31 |
| 2026-03-02 | -2.46 |
| 2026-02-27 | -2.41 |
| 2026-02-26 | -2.33 |
| 2026-02-25 | -2.27 |
| 2026-02-24 | -2.15 |
| 2026-02-23 | -2.11 |
| 2026-02-20 | -2.17 |
| 2026-02-19 | -2.24 |
| 2026-02-18 | -2.10 |
| 2026-02-17 | -2.14 |
| 2026-02-13 | -2.13 |
| 2026-02-12 | -2.22 |
| 2026-02-11 | -2.26 |
| 2026-02-10 | -2.36 |
| 2026-02-09 | -2.74 |
| 2026-02-06 | -2.75 |
| 2026-02-05 | -2.73 |
| 2026-02-04 | -2.86 |
| 2026-02-03 | -2.89 |
| 2026-02-02 | -2.87 |
| 2026-01-30 | -2.97 |
| 2026-01-29 | -3.09 |
| 2026-01-28 | -2.93 |
| 2026-01-27 | -3.57 |
| 2026-01-26 | -3.69 |
| 2026-01-23 | -3.67 |
| 2026-01-22 | -4.25 |
| 2026-01-21 | -4.00 |